Endotronix

Endotronix is a digital health medtech company founded in 2007 and headquartered in the United States. The company's slogan, "Advancing the Treatment of Heart Failure. Together.", reflects its mission to develop innovative solutions for advanced heart failure patients. The Cordella™ Heart Failure System is its flagship product, featuring a cloud-based disease-management system and a breakthrough implantable wireless pulmonary artery pressure sensor. This integrated platform facilitates proactive management and early detection of worsening heart failure, leading to ongoing therapeutic interventions and improved quality of life for patients. In September 2018, Endotronix secured a significant $70.00M Series D investment from a group of prominent investors including SV Health Investors, Aperture Venture Partners, BioVentures Investors, Life Science Partners, Lumira Ventures, Seroba Life Sciences, Wanxiang Healthcare, OSF Ventures, and Skydeck. This investment not only highlights the confidence of the investor community in Endotronix's vision and potential but also provides the necessary financial resources to further develop and bring to market its innovative health management tools. As Endotronix continues to make strides in the biotechnology and health care industries, the company's focus on driving positive patient outcomes, reducing hospital readmissions, and ultimately lowering care costs positions it as a compelling player in the medtech space.